

Transforming Gynecology: ASPIVIX and Titus Health Care Announce Distribution Partnership in the Benelux



Epalinges, Switzerland/Los Angeles, California (USA) – June 20, 2025 – ASPIVIX is pleased to announce a strategic distribution agreement with Titus Health Care to bring Carevix®, our innovative non-traumatic suction cervical stabilizer, to healthcare providers and patients in the Netherlands, Belgium and Luxembourg. This partnership marks another step forward in our mission to modernize gynecology with solutions that put women's comfort and experience first.

Titus Health Care, based in the Netherlands, is a leading player in women's health and fertility. Known for its strong clinical network and commitment to innovation, Titus is an ideal partner to expand access to Carevix®—our CE-marked device designed to reduce pain and bleeding during transcervical procedures, such as intrauterine device (IUD) placement.

Fear of pain during IUD insertion remains a major barrier to adoption, affecting 30% to 45% of women globally, an estimated 120 million women each year, primarily due to the use of the traditional cervical tenaculum.

In the ADVANCE Women Study, a single-blinded, randomized, multicenter comparative trial, Carevix® demonstrated a 73% reduction in pain and 78% reduction in bleeding during IUD placement compared to the standard tenaculum becoming a new alternative for better patient experience.

Joep de Mönnink, Founder & Director of Titus Health Care, shares “At Titus Health Care, we are committed to offering solutions that truly improve the experience of women and their care providers. Carevix® represents an important step toward more respectful, pain-conscious gynecology. We're excited to bring this innovation to the Netherlands and Belgium, empowering clinicians with tools that reflect the care women deserve.”

Mathieu Horras, ASPIVIX CEO & Co-Founder, adds “We're proud to partner with Titus Health Care, whose reputation and reach in the Benelux region will help accelerate access to Carevix®. Together, we're enabling a shift toward gentler, more modern care, helping women make informed choices adopting IUD without the fear of pain and bleeding.”

With this agreement, ASPIVIX reinforces its growing presence in Europe. The launch of Carevix® in the Netherlands and Belgium marks a meaningful step forward in redefining gynecological procedures—from IUD insertions to IVF treatments—by putting patient comfort and dignity at the center of care.

Reference:

1. Michal Yaron, Hélène Legardeur, Bastien Barcellini, Farida Akhoundova, Patrice Mathevet, Safety and efficacy of a suction cervical stabilizer for IUD insertion: results from a randomized, controlled study, Contraception, 2023, 110004, ISSN 0010-7824, Contraception link



About Aspivix

Aspivix is a pioneering leader in women's health, dedicated to modernizing healthcare solutions for women around the world. Focused on innovation, Aspivix develops is committed to cutting-edge medical devices, such as carevix®, designed to transform the gynecological experience by offering safer and less painful solutions that enhance the quality of care and empower women to take control of their health.

Further information at www.aspivix.com.

About carevix®

carevix® is an innovative, soft-suction cervical device designed as a modern and gentler alternative to the traditional cervical tenaculum significantly reducing trauma, pain and bleeding associated with transcervical procedures. carevix® received FDA-clearance, CE-Mark, MHRA and ANVISA approval, and is available for commercialization in Switzerland, in the UK; other countries will be available in the upcoming months.

carevix® has been clinically proven to be non-traumatic during transcervical procedures with compelling results from the ADVANCE Women, a multisite randomized controlled trial of carevix®, used In IUD Procedures against the cervical tenaculum has been published in "Contraception", the International Reproductive Health Journal in 2023.

Recognized as one of the Best Inventions in 2024 by TIME Magazine, carevix® was honored with the 2022 iF Design Award 2022, one of the most important and prestigious design awards in the world, amongst other recognitions.



About Titus Health Care

Titus Health Care provides gynecological products and training to enhance women's healthcare. In 2010, Titus Health Care launched the T-Safe IUD in the Netherlands for women seeking hormone-free contraception. Over the years, our product range has grown considerably. Since 2021, Titus Health Care is also a distributor in Belgium, and Luxembourg. Every year, Titus Health Care educates and trains over 2.000 healthcare professionals on long-acting contraceptive insertion techniques and advise them on contraception. Titus Health Care is also focused on the field of fertility.

Further information at www.titushealthcare.be and www.titushealthcare.nl.

Aspivix
Mathieu Horras

Mathieu Horras
CEO & Co-Founder

Titus Health Care

Joep de Mönnink
Founder & Director